dc.contributor.author | Ros, S | |
dc.contributor.author | Wright, AJ | |
dc.contributor.author | Bruna, A | |
dc.contributor.author | Caldas, C | |
dc.contributor.author | Brindle, KM | |
dc.date.accessioned | 2021-07-13T15:19:11Z | |
dc.date.available | 2021-07-13T15:19:11Z | |
dc.date.issued | 2021-09-17 | |
dc.identifier.citation | STAR protocols, 2021, 2 (3), pp. 100608 - ? | |
dc.identifier.issn | 2666-1667 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4685 | |
dc.identifier.eissn | 2666-1667 | |
dc.identifier.doi | 10.1016/j.xpro.2021.100608 | |
dc.description.abstract | 13C nuclear spin hyperpolarization can increase the sensitivity of detection in an MRI experiment by more than 10,000-fold. 13C magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized 13C label exchange between injected [1-13C]pyruvate and the endogenous tumor lactate pool can be used clinically to assess tumor grade and response to treatment. We describe here an experimental protocol for using this technique in patient-derived and established cell line xenograft models of breast cancer in the mouse. For complete details on the use and execution of this protocol, please refer to Ros et al. (2020). | |
dc.format | Electronic-eCollection | |
dc.format.extent | 100608 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.title | Metabolic imaging with hyperpolarized [1-13C] pyruvate in patient-derived preclinical mouse models of breast cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-09-17 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.xpro.2021.100608 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | STAR protocols | |
pubs.issue | 3 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Preclinical Modelling of Paediatric Cancer Evolution | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Preclinical Modelling of Paediatric Cancer Evolution | |
pubs.publication-status | Accepted | |
pubs.volume | 2 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Preclinical Modelling of Paediatric Cancer Evolution | |
icr.researchteam | Preclinical Modelling of Paediatric Cancer Evolution | |
dc.contributor.icrauthor | Bruna Cabot, Alejandra | |